Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Autoimmune hemolytic anemia (ALHA) cardioplegic solution and preparation method thereof

A technique for cardioplegia solution and solution, applied in the field of cardioplegia solution, can solve the problems of prone to arrhythmia, prone to inflammatory reaction, long asystole time, etc., so as to improve the success rate of one resuscitation and shorten the asystole. time, the effect of avoiding myocardial damage

Inactive Publication Date: 2014-07-02
THE FIRST TEACHING HOSPITAL OF XINJIANG MEDICAL UNIVERCITY
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0012] The present invention provides an ALHA cardioplegia solution and a preparation method thereof, which overcomes the deficiencies of the above-mentioned prior art, and can effectively solve the problem that the traditional cardioplegia solution induces a too long arrest time and requires reperfusion and re-beating. prone to arrhythmia, myocardial damage, inflammatory reactions and inability to carry oxygen

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Autoimmune hemolytic anemia (ALHA) cardioplegic solution and preparation method thereof
  • Autoimmune hemolytic anemia (ALHA) cardioplegic solution and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Example 1, the ALHA cardioplegia solution contains 552.86mg to 947.76mg of adenosylcobalamin, 4.739ml to 5ml of lidocaine solution with a mass concentration of 2%, and pentazocine per 500ml of the ALHA cardioplegia solution. 30mg to 60mg, 4.1ml to 10ml of magnesium sulfate solution with mass concentration of 25%, 3.725ml to 5ml of potassium chloride solution with mass concentration of 10%, 4.3ml to 10ml of calcium gluconate solution with mass concentration of 10%, and the balance Acetate Ringer's solution; wherein, the ALHA cardioplegia solution is obtained by the following method: at a room temperature of 22°C to 26°C, oxygen is injected into the hyperoxic liquid at an oxygen flow rate of 2 L / min to 4L / min. In the instrument, the oxygen after the reaction is fed into the required amount of Ringer's acetate for dissolved oxygen activation treatment, and after dissolving oxygen, it is prepared into a hypertonic oxygen ringer's acetate whose partial pressure of oxygen in...

Embodiment 2

[0022] Example 2, the ALHA cardioplegia solution contains 552.86 mg or 947.76 mg of adenosylcobalamin, 4.739 ml or 5 ml of lidocaine solution with a mass concentration of 2%, and pentazocine in every 500 ml of the ALHA cardioplegia solution. 30mg or 60mg, 4.1ml or 10ml of magnesium sulfate solution with mass concentration of 25%, 3.725ml or 5ml of potassium chloride solution with mass concentration of 10%, 4.3ml or 10ml of calcium gluconate solution with mass concentration of 10%, and the balance Acetate Ringer's solution; wherein, the ALHA cardioplegia solution is obtained by the following method: at a room temperature of 22 ° C or 26 ° C, oxygen is injected into the hyperoxic liquid at an oxygen flow rate of 2 L / min or 4 L / min. In the instrument, the oxygen after the reaction is fed into the required amount of Ringer's acetate for dissolved oxygen activation treatment, and after dissolving oxygen, it is prepared into hypertonic oxygen Ringer's acetate with an oxygen partial...

Embodiment 3

[0023] Embodiment 3, the preparation method of this ALHA cardioplegia solution, every 500ml of this ALHA cardioplegia solution contains adenosylcobalamin 552.86mg to 947.76mg, mass concentration is 2% lidocaine solution 4.739ml to 5ml, spray Tazocine 30mg to 60mg, 25% magnesium sulfate solution 4.1ml to 10ml, 10% potassium chloride solution 3.725ml to 5ml, 10% calcium gluconate solution 4.3ml to 10ml and the remaining amount of Ringer's acetate solution; wherein, the preparation method of the ALHA cardioplegia solution is carried out according to the following steps: at a room temperature of 22°C to 26°C, with an oxygen flow rate of 2 L / min to 4L / min Input oxygen into the hyperoxic liquid preparation apparatus, and pass the reacted oxygen into the required amount of acetic acid Ringer's solution for oxygen-dissolving activation treatment. After dissolving oxygen, prepare a hypertonic liquid with an oxygen partial pressure of 100kPa to 120kPa in the solution. Oxygenated Ringe...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of cardioplegia, and relates to an ALHA cardioplegia and a preparation method thereof. The ALHA cardioplegia contains 552.86 mg to 947.76 mg of adenosylcobalamin per 500 ml of the ALHA cardioplegia, Lidocaine solution with a mass concentration of 2% is 4.739ml to 5ml, pentazocine is 30mg to 60mg, and magnesium sulfate solution with a mass concentration of 25% is 4.1ml to 10ml. The present invention can effectively shorten the time of cardiac arrest during the operation, because the ALHA cardioplegia can carry oxygen, so the use of a small amount of ALHA cardioplegia can effectively arrest the heart, avoiding myocardial ischemia and reperfusion Damage to the myocardium can improve the success rate of a re-beat and reduce the incidence of arrhythmia after a re-beat, and effectively reduce the inflammatory response and effectively protect the myocardial cells.

Description

technical field [0001] The invention relates to the technical field of cardioplegia solution, and relates to an ALHA cardioplegia solution and a preparation method thereof. Background technique [0002] Since the beginning of heart surgery in the 1960s, pioneers in cardiac surgery have attempted several ways to support the patient's circulation on the one hand and protect the heart on the other. The protective effect of hypothermia has been recognized not only locally in the heart but also in systemic applications. The subsequent development of cardiac surgery has mainly utilized the gradual improvement of extracorporeal circulation components, allowing more and more complex and longer operations to be performed, but unfortunately, the myocardial protection effect has not reached the ideal state, and cardiac arrest still exists after surgery - Reperfusion injury. Therefore, it is necessary to provide a measure of myocardial protection that is better than merely cooling the...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K33/14A61P9/00A61K33/06A61K33/00A61K31/714A61K31/439A61K31/167
Inventor 郑宏王江陈春玲马明闵晓艳
Owner THE FIRST TEACHING HOSPITAL OF XINJIANG MEDICAL UNIVERCITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products